Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRA: Rilvegostomig and Dato-DXd Combinations in Advanced NSCLC
NCT07098338Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2025
- Primary completion
- Apr 2029
- Modality
- Small Molecules, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 12
01
Overview
A Phase 2 trial of rilvegostomig, datopotamab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Aug 2025; status: recruiting.
02
Drugs
rilvegostomigdatopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07098338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07098338.